RxDoctor Payments Data

Khushwinder Garcha, MD

Internal Medicine · Roseville, CANPI 1417120783

Payments from drug & device makers

$3,969in general payments, 2019–2025

Across 197 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$821
  • AbbVie$438
  • AstraZeneca$385
  • GSK$321
  • Lilly USA, LLC$242
  • Astellas Pharma US Inc$231
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,969 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$329,718
Medicare patients
451
Services billed
5,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$117,277
EliquisApixaban73$80,411
JardianceEmpagliflozin42$62,570
RybelsusSemaglutide17$34,925
FarxigaDapagliflozin Propanediol24$34,062
MounjaroTirzepatide16$29,163
XareltoRivaroxaban26$26,130
TrulicityDulaglutide11$25,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$4,977
Dofetilide12$4,650
Levothyroxine Sodium222$4,203
Rosuvastatin Calcium193$4,088
Atorvastatin Calcium282$3,057
Gabapentin143$2,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$821$152,20273 claims
PfizerEliquis, Paxlovid$203$81,84089 claims
Boehringer IngelheimJardiance$202$62,57042 claims
Lilly USA, LLCMounjaro, Trulicity$242$54,72927 claims
AstraZenecaFarxiga$385$34,06224 claims
Johnson & JohnsonXarelto$134$26,13026 claims
GSKTrelegy Ellipta$321$14,42017 claims
AbbVieSynthroid$438$2,03320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →